Curing Incurable Cancer

Opinion

“Foremost among the way humans organize themselves into communities are ‘us versus them’ distinctions” [1]. Among the most devastating of these is the terminal prognosis: “This disease is likely to kill you soon. Prepare to die.” It puts patients on death row, and, often, into solitary confinement. It’s not how anyone wants to die. But it’s a common consequence of cancer. Of the almost two million cancers diagnosed each year, a fourth or so will kill their host. Yet the terminal prognosis is rarely warranted, for there is always legitimate hope for a cancer cure, and never legitimate hope of avoiding death for long.


Read More About This Article: https://crimsonpublishers.com/nacs/fulltext/NACS.000645.php

Read More Crimson Publishers Google Scholar Articles: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=3gM53m4AAAAJ&citation_for_view=3gM53m4AAAAJ:8k81kl-MbHgC

Comments

Post a Comment

Popular posts from this blog

Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme_Crimson Publishers

Image
  Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme by Siddharth Shah in  in Novel Approaches in Cancer Study Abstract Glioblastoma Multiforme (GBM, WHO grade IV) is one of the most aggressive, invasive, and lethal intracranial neoplasms, with a low post-diagnosis survival rate. Standard-of-care treatment regimens involving maximal surgical resection, radiotherapy, and genetic anti-tumor compounds like Temozolomide have only been marginally effective in improving overall survival and quality of life. Cell fusion, autophagy, and other complex biological processes affecting GBM pathophysiology are being studied to improve GBM treatment. This paper therefore focuses on oncolytic virus therapy combined with surgical resection, photodynamic therapy, and novel gene therapy, demonstrating how GBM treatment for patients could result in immediate and authentic tumor cytotoxicity and removal, rather than treatment of recurrent GBM. Standard therapy for GBM,...
Read more

Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases

Abstract Inorganic phosphate (Pi) is essential for several biochemical reaction. Serum Pi is maintained at relatively narrow range concentrations, between 0.7 and 1.55mM. Tumor microenvironment presents a high Pi concentration (1.8±0.2mM Pi) and this could be associated wi the rapid growth in the “Growth Rate Hypothesis”. Several studies have identified high expression of Pi transporters in various tumor tissues. Similarly, ecto-enzymes (like ecto-nucleotidases or ecto- phosphates) act by dephosphorylating phosphosubstrates in the extracellular environment, and its high expression has been observed in various types of cancer. Little is known about the function of these ecto-enzymes on Pi releasing and accumulation in the tumor environment. Therefore, the purpose of this study is to correlate a possible contribution of the Pi release in the tumor microenvironment by ecto-nucleotidases and ecto-phosphatases, concomitant to the regulation of Pi extracellular pool by specific Pi...
Read more

Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases_Crimson Publishers

Image
Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases by Marco Antonio Lacerda-Abreu and José Roberto Meyer- Fernandes in Journal of Cancer Research Crimson Publishers _  Novel Approaches in Cancer Study Inorganic phosphate (Pi) is essential for several biochemical reaction. Serum Pi is maintained at relatively narrow range concentrations, between 0.7 and 1.55mM. Tumor microenvironment presents a high Pi concentration (1.8±0.2mM Pi) and this could be associated wi the rapid growth in the “Growth Rate Hypothesis”. Several studies have identified high expression of Pi transporters in various tumor tissues. Similarly, ecto-enzymes (like ecto-nucleotidases or ecto- phosphates) act by dephosphorylating phosphosubstrates in the extracellular environment, and its high expression has been observed in various types of cancer. Little is known about the function of these ecto-enzymes on Pi releasing and accumulation in the tu...
Read more